Neuropharmacology

Allosteric Modulation of GPCR Signaling Pathways

Investigation of allosteric binding sites on G-protein coupled receptors to develop selective modulators with improved therapeutic windows and reduced off-target effects.

RESEARCH GAP FRONTIERS

Neuroinflammation and Microglial Pharmacology

Study of pharmacological interventions targeting microglial activation and neuroinflammatory cascades in neurodegeneration and psychiatric disorders.

RESEARCH GAP FRONTIERS

Blood-Brain Barrier Permeability Optimization

Development of drug delivery strategies and molecular modifications to enhance CNS penetration while maintaining specificity and minimizing peripheral effects.

RESEARCH GAP FRONTIERS

NMDA Receptor Subtype Selectivity and Neuroprotection

Exploration of subunit-specific NMDA receptor pharmacology for neuroprotective compounds that dissociate excitotoxicity from physiological synaptic function.

RESEARCH GAP FRONTIERS

Dopamine D1-D2 Heteromer Pharmacology

Investigation of receptor oligomerization and allosteric interactions between dopamine D1 and D2 receptors as novel drug targets in movement disorders.

RESEARCH GAP FRONTIERS

Endocannabinoid System Modulation in Pain

Research on cannabinoid receptor agonists and endocannabinoid reuptake inhibitors for chronic pain management with reduced addiction liability.

RESEARCH GAP FRONTIERS

Histone Deacetylase Inhibitors in Neuropsychiatry

Development of HDAC inhibitors targeting epigenetic mechanisms in cognitive enhancement, depression, and neurodevelopmental disorders.

RESEARCH GAP FRONTIERS

Astrocyte-Neuron Signaling and Pharmacology

Study of gliotransmitter release and astrocytic receptor pharmacology to modulate synaptic plasticity and neuroprotection.

RESEARCH GAP FRONTIERS

Serotonin 5-HT7 Receptor and Circadian Rhythms

Investigation of 5-HT7 receptor pharmacology and its role in circadian phase adjustment and mood disorder treatment.

Acid-Sensing Ion Channel Modulation

Development of ASIC channel blockers and modulators for chronic pain, anxiety, and ischemic stroke neuroprotection.

Neurotrophin Signaling and Receptor Pharmacology

Research on selective TrkA, TrkB, and TrkC agonists and p75NTR modulators for neurodegenerative disease treatment.

Tau Protein Aggregation Pharmacological Intervention

Development of compounds targeting tau phosphorylation, aggregation, and propagation in Alzheimer''s disease and tauopathies.

Voltage-Gated Sodium Channel Isoform Selectivity

Design of subtype-selective sodium channel blockers targeting neuronal isoforms for pain and epilepsy without cardiac side effects.

P2X and P2Y Purinergic Receptor Pharmacology

Investigation of ATP and adenosine receptor signaling in neuropathic pain, neuroinflammation, and synaptic transmission.

Orexin Receptor Antagonists in Sleep Disorders

Development of selective OX1R and OX2R antagonists for insomnia treatment with improved sleep maintenance and safety profiles.

Glycine Receptor Modulation and Spasticity

Research on glycine receptor potentiators and selective modulators for treating spasticity and motor hyperexcitability.

Sigma-1 Receptor Neuroprotection Mechanisms

Study of sigma-1 receptor agonists in neuropathic pain, depression, and cognitive dysfunction with molecular mechanism elucidation.

Kynurenine Pathway and Neuropsychiatric Disease

Investigation of kynurenine metabolism modulators and NMDA antagonism for depression, schizophrenia, and cognitive impairment.

Transient Receptor Potential Channel Pharmacology

Development of selective TRPV1, TRPM8, and TRPA1 modulators for chronic pain, temperature sensation, and neuroprotection.

Phosphodiesterase Inhibitors in Cognition

Research on PDE4, PDE5, and PDE10 inhibitors for cognitive enhancement, depression, and ADHD treatment.

Metabotropic Glutamate Receptor Modulation

Development of mGluR allosteric modulators as alternatives to orthosteric agonists with improved selectivity and reduced dyskinesia.

Muscarinic M1 Receptor Agonists in Alzheimer''s

Design of selective M1 acetylcholine receptor agonists for cognitive enhancement and neuroprotection in Alzheimer''s disease.

Nicotinic Receptor Subtype Selectivity

Investigation of alpha7 and alpha4beta2 nicotinic agonists for cognitive deficits, pain, and neuroinflammatory modulation.

Neuropeptide Y and Appetite Regulation

Study of NPY receptor subtype pharmacology in feeding behavior, anxiety, and metabolic-neuropsychiatric comorbidities.

Opioid Receptor Pharmacology and Addiction

Development of biased mu-opioid ligands and selective delta-opioid agonists for analgesia with reduced addiction potential.

Substance P Neurokinin Antagonism in Pain

Research on NK1 and NK3 receptor antagonists for chronic pain and mood disorders based on neuroinflammatory targets.

Neuromodulator Transporter Inhibition Selectivity

Design of selective norepinephrine, serotonin, and dopamine transporter inhibitors with improved therapeutic ratios and minimal drug interactions.

Adenosine Receptor Subtype A1 vs A2A

Investigation of adenosine receptor subtype-selective antagonists for Parkinson''s disease and neurodegenerative conditions.

Amyloid-Beta Oligomer Targeted Therapeutics

Development of compounds specifically targeting neurotoxic amyloid-beta oligomers rather than plaques in Alzheimer''s disease.

GABA-A Receptor Subunit Selective Modulation

Design of alpha2/alpha3-selective GABAergic compounds for anxiety without sedation or tolerance development.

Chemokine Receptor Antagonism in Neuroprotection

Research on CCR2 and CCR5 antagonists for modulating neuroinflammation and microglial recruitment in neurodegenerative diseases.

Brain-Derived Neurotrophic Factor Modulation

Investigation of compounds enhancing BDNF signaling or mimicking its effects for depression, anxiety, and cognitive decline.

Lysergamide Receptor Pharmacology Mechanisms

Study of serotonin 5-HT2A/1B/7 receptor interactions underlying psychedelic and therapeutic effects in depression and PTSD.

Glycine Transporter Inhibition for Schizophrenia

Development of GlyT1 inhibitors to enhance N-methyl-D-aspartate receptor function for cognitive and negative symptoms.

Protease-Activated Receptor Neuroprotection

Research on PAR1 and PAR4 modulation in neuroinflammation, stroke, and neurodegenerative disease progression.

Lysine-Specific Demethylase Inhibitors Cognition

Investigation of LSD1 inhibitors for enhancing memory consolidation and treating cognitive symptoms in neuropsychiatric disorders.

Oxytocin Receptor and Social Cognition

Study of oxytocin and oxytocin receptor modulators for social deficits in autism spectrum disorder and schizophrenia.

Estrogen Receptor Neuroprotection in Menopause

Research on selective estrogen receptor modulators for cognitive decline and mood symptoms in perimenopause and menopause.

Alpha-Synuclein Aggregation Pharmacotherapy

Development of compounds targeting alpha-synuclein misfolding and propagation in Parkinson''s disease and Lewy body dementia.

Calcineurin Inhibition and Memory Enhancement

Investigation of selective calcineurin inhibitors for enhancing long-term potentiation without immunosuppressive effects.

TLR4 Antagonism in Neuroinflammation

Research on toll-like receptor 4 antagonists for modulating microglial activation in pain, depression, and neurodegeneration.

Kainate Receptor Positive Allosteric Modulation

Study of kainate receptor PAMs for enhancing synaptic transmission and cognitive function with neuroprotective benefits.

Nociceptin Receptor Analgesia and Mood

Investigation of ORL-1 receptor ligands for pain management with mood enhancement and reduced addiction potential.

Brain Imaging Biomarker Pharmacodynamics

Development of neuroimaging protocols to assess central nervous system drug target engagement and therapeutic mechanisms.

Optogenetic Pharmacology Validation Methods

Use of optogenetic tools to validate pharmacological mechanisms and circuit-specific effects of neurochemical manipulations.

Cerebrospinal Fluid Biomarker Pharmacology

Research on CSF biomarkers of drug target engagement and CNS drug efficacy in neurodegenerative and psychiatric diseases.

Quantitative Systems Pharmacology Neurotransmission

Development of computational models integrating receptor signaling, transporter kinetics, and circuit dynamics for drug optimization.

Organoid Pharmacology and Disease Modeling

Use of brain organoid systems for high-throughput screening of neurochemical compounds and disease-specific drug responses.

Electrophysiology-Guided Drug Discovery Platforms

Integration of whole-cell patch-clamp and multi-electrode array technologies for phenotypic screening of neuronal activity modulators.

Pharmacogenomic Variations in Drug Metabolism

Investigation of CYP450 and transporter genetic polymorphisms affecting CNS drug bioavailability and therapeutic response.

Liquid-Liquid Phase Separation in Neuronal Condensates

Investigation of biomolecular condensate formation and pharmacological modulation of phase-separated protein assemblies in synaptic plasticity and neurodegeneration.

Cryo-EM Structure-Based Drug Design Neurotransmission

Utilization of cryo-electron microscopy structures to rationally design ligands targeting conformationally dynamic ion channels and receptors.

Cannabinoid CB2 Receptor Immunomodulation Neuroinflammation

Selective CB2 agonism for peripheral immune cell infiltration control and microglial activation suppression in neurodegenerative diseases.

Lysyl Oxidase-Like Inhibition Amyloidosis Prevention

Pharmacological targeting of extracellular matrix cross-linking enzymes to prevent amyloid-beta and tau protein fibrillization and propagation.

Soluble N-Ethylmaleimide-Sensitive Factor Attachment Protein Modulation

Drug development targeting SNARE complex assembly machinery to enhance or inhibit synaptic vesicle release mechanisms.

Cyclin-Dependent Kinase 5 Inhibition in Neurodegeneration

CDK5 kinase inhibitor development for preventing tau phosphorylation and synaptic loss in Alzheimer''s disease and related tauopathies.

Transthyretin Stabilization Amyloid Transthyretin Neuropathy

Pharmacological stabilization of transthyretin tetrameric structure to prevent amyloid fibril formation in hereditary and wild-type ATTR amyloidosis.

Ketamine-Like NMDA Antagonist Rapid Antidepressant Effects

Investigation of non-ketamine NMDA channel blockers producing rapid-onset antidepressant and anxiolytic effects through alternative mechanisms.

Sodium-Glucose Cotransporter SGLT1 Neuroenergetics Modulation

Pharmacological modulation of neuronal glucose uptake pathways to enhance cerebral energy metabolism in neurodegenerative conditions.

G-Protein-Coupled Receptor Kinase Inhibition Signal Prolongation

GRK inhibitor development to extend GPCR signaling duration and enhance therapeutic efficacy of monoamine receptor targeting.

Retinoid X Receptor LXR Agonist Neuroinflammation

Nuclear receptor agonist development for lipid homeostasis restoration and microglial activation suppression in neuroinflammatory diseases.

Tetrahydrobiopterin Synthesis Augmentation Monoamine Restoration

Pharmacological enhancement of BH4 cofactor biosynthesis to restore compromised dopamine and serotonin synthesis in neuropsychiatric disorders.

Apolipoprotein E Isoform-Specific Tau Pathology Targeting

Development of APOE4-selective pharmacotherapies to modulate tau aggregation and neuroinflammation in APOE4-associated Alzheimer''s disease.

Potassium Channel Opener IKCa Modulation Neuronal Excitability

Targeting intermediate-conductance calcium-activated potassium channels to regulate neuronal excitability and prevent excitotoxicity.

FKBP12 Immunophilin Neuroprotection Ryanodine Receptor

Manipulation of FKBP12-ryanodine receptor interactions to modulate calcium release and prevent excitotoxic neuronal death.

Proteolytic Cleavage Site-Specific Amyloid Precursor Protein

Selective inhibition of beta-secretase and gamma-secretase cleavage pathways to reduce amyloid-beta production without affecting Notch signaling.

Semicarbazide-Sensitive Amine Oxidase Inhibition Neuroinflammation

Targeting vascular adhesion protein-1 to reduce immune cell infiltration and neuroinflammatory responses in central nervous system diseases.

Huntingtin Protein Aggregation Proteostasis Enhancement

Pharmacological interventions targeting protein chaperone systems and proteasomal degradation to manage mutant huntingtin toxicity.

Sphingosine-1-Phosphate Receptor Subtype S1P1 Immunomodulation

S1P1-selective modulation to control lymphocyte trafficking and reduce neuroinflammatory infiltration in multiple sclerosis and neuroinflammatory conditions.

Nrf2 Antioxidant Response Element Activation Neurodegeneration

Small molecule activators of nuclear factor erythroid 2-related factor 2 pathway for enhancing endogenous antioxidant defense mechanisms.

Olfactory Receptor De-orphanization Neurological Drug Targets

Discovery and pharmacological characterization of ligands for orphaned olfactory GPCRs expressed in central nervous system neurons.

Microtubule-Associated Protein Tau Kinase Selectivity

Development of kinase inhibitors selectively targeting tau-phosphorylating enzymes while minimizing off-target effects on cell cycle regulation.

Glial Cell Line-Derived Neurotrophic Factor Receptor GFRalpha

Pharmacological targeting of GDNF co-receptor signaling to enhance neuroprotection without direct receptor agonism.

Mitochondrial Permeability Transition Pore Antagonism Neuroprotection

Inhibition of mitochondrial outer membrane permeabilization to prevent cytochrome c release and apoptotic neuronal death.

Pannexin-1 Gap Junction Channel Modulation Neuroinflammation

Selective antagonism of pannexin-1 hemichannels to reduce ATP release and suppress microglial inflammatory responses.

Vasoactive Intestinal Peptide Receptor VPAC Neuroprotection

VPAC receptor subtype-selective agonists for promoting neuronal survival and reducing neuroinflammatory responses.

Tetrahydrocannabinol Isomer Selectivity Therapeutic Potential

Investigation of stereoisomeric and positional isomers of THC for differential CB1/CB2 selectivity and therapeutic efficacy.

Neuronal Pentraxin NPTX2 Synapse Elimination Modulation

Pharmacological targeting of pentraxin-mediated complement activation to prevent pathological synapse pruning and loss.

Complement Component C3 Cascade Inhibition Neuroinflammation

Small molecule inhibitors of complement pathway components to reduce neuroinflammation and prevent microglial complement-dependent synapse elimination.

Nicotinamide Adenine Dinucleotide Salvage Pathway Enhancement

Pharmacological augmentation of NAD+ biosynthesis and metabolism to enhance neuroprotection and mitochondrial function.

Sirtuin-1 NAD-Dependent Deacetylase Neuronal Longevity

SIRT1 activation strategies to promote neuronal survival pathways and enhance cognitive reserve in aging.

Poly-ADP-Ribose Polymerase Inhibition Excitotoxicity Prevention

PARP inhibitors to prevent DNA damage-induced energy depletion and neuronal death following excitotoxic stress.

GLP-1 Receptor Agonist Neuroprotection Type 2 Diabetes

CNS-penetrant GLP-1 receptor agonists for treating neurodegeneration associated with metabolic dysfunction and diabetes.

Lysophosphatidic Acid Receptor LPA5 Neuroinflammation Modulation

LPA receptor subtype selectivity development for differential modulation of neuroinflammation and glial activation.

Phospholipase D Signaling Vesicle Trafficking Enhancement

PLD modulation to enhance synaptic vesicle dynamics and neurotransmitter release probability.

Prostaglandin E2 Receptor EP4 Agonism Anti-Inflammatory Neuroprotection

EP4-selective prostaglandin agonists for promoting neuroprotection through non-canonical anti-inflammatory signaling pathways.

Toll-Like Receptor TLR2 Antagonism Sterile Neuroinflammation

TLR2 selective antagonism to prevent endogenous DAMP-induced microglial activation without immunosuppression.

Formyl Peptide Receptor FPR1 Anti-Inflammatory Microglia

FPR1 agonist development to promote resolution phase microglial phenotypes and reduce pro-inflammatory cytokine production.

Neural Wiskott-Aldrich Syndrome Protein N-WASP Synaptic Plasticity

Pharmacological modulation of actin cytoskeleton remodeling proteins to enhance dendritic spine morphogenesis and synaptic strength.

Reelin Signaling Pathway Enhancement Cognitive Improvement

Augmentation of reelin-VLDLR signaling to promote synaptic plasticity and prevent cognitive decline in neurodegenerative diseases.

Brain-Specific Angiogenesis Inhibitor BAI1 Synapse Stability

BAI1 receptor modulation to regulate phagocytosis-mediated synapse elimination and promote synaptic stability.

Synaptotagmin Calcium Sensor Modulation Vesicle Release

Small molecule modulators of synaptotagmin calcium-binding properties to alter neurotransmitter release kinetics.

Dynorphin Kappa Opioid Receptor Stress-Induced Dysphoria

Kappa opioid receptor antagonists targeting the endogenous dynorphin system to prevent stress-induced depressive symptoms.

Neuropeptide FF Opioid Modulation Analgesic Tolerance Prevention

NPFF receptor modulation to prevent opioid-induced tolerance and enhance analgesic efficacy.

Tachykinin NK3 Receptor Modulation Stress Neuroadaptation

NK3 receptor antagonists for preventing maladaptive neuroadaptations following chronic stress exposure.

Neurokinin Receptor Antagonism Emetic Control and Anxiety

Triple neurokinin receptor antagonists targeting NK1-NK3 subtypes for dual anxiolytic and antiemetic efficacy.

Cholecystokinin CCK-B Receptor Modulation Anxiety Disorders

CCK-B receptor selective antagonism for treating anxiety disorders with distinct pharmacological profile from benzodiazepines.

Melanin-Concentrating Hormone MCHR1 Antagonism Appetite Control

MCHR1 selective antagonists for modulating hypothalamic appetite circuits and promoting neuroprotection.

Galanin GAL1 Receptor Subtype Memory Enhancement

GAL1-selective modulation to enhance cholinergic neurotransmission and improve cognitive function in memory disorders.

Motilin Receptor Agonism Gastric-Neural Neuroprotection Axis

Motilin receptor targeting to modulate the gut-brain axis and promote neuroprotection through enteric-CNS signaling.

Synaptic Vesicle Release Machinery Modulation

Investigates pharmacological targeting of SNARE complex proteins and calcium-dependent exocytosis mechanisms to enhance or inhibit neurotransmitter release.

Astrocytic Gap Junction Coupling Pharmacology

Examines connexin-based intercellular communication modulation in astrocytes to regulate neuroinflammatory responses and metabolic support.

Mitochondrial Dysfunction in Neurodegeneration

Develops pharmacological interventions targeting mitochondrial biogenesis, oxidative phosphorylation, and calcium handling in neurodegenerative diseases.

Liquid-Liquid Phase Separation Modulation

Explores drug targeting of biomolecular condensates and protein phase separation dynamics in neuronal compartments and synaptic plasticity.

Olfactory Receptor Signaling in Brain

Investigates non-canonical functions of olfactory GPCRs expressed in neural circuits and their pharmacological modulation for neurological disorders.

Excitatory-Inhibitory Balance Restoration Pharmacology

Develops therapeutic strategies to restore disrupted E-I balance through targeted modulation of excitatory and inhibitory neurotransmitter systems.

Circadian Clock Gene Expression Modulation

Studies pharmacological manipulation of CLOCK, BMAL1, and PER genes to treat sleep disorders and mood dysregulation.

Glymphatic System Enhancement Pharmacology

Develops drugs that enhance glial-driven clearance of neurotoxic proteins and metabolic wastes from the central nervous system.

Epileptic Focus Pharmacological Silencing

Investigates localized pharmacological suppression of aberrant neuronal activity in epileptogenic zones using novel anticonvulsant approaches.

Neuronal Lipid Raft Organization Modulation

Examines pharmacological targeting of cholesterol and sphingolipid-dependent membrane microdomains in signal transduction and neurodegeneration.

CREB Transcription Factor Activation Enhancement

Develops small molecules and peptides that enhance CREB-mediated gene transcription for memory formation and neuroprotection.

Retinoid Acid Signaling in Neuroplasticity

Investigates retinoic acid receptor agonists and antagonists to modulate synaptic plasticity and recovery after neural injury.

Postsynaptic Density Scaffold Protein Modulation

Studies pharmacological targeting of PSD-95, Homer, and Shank proteins to regulate synaptic strength and plasticity.

Neuroinflammatory Lipid Mediator Pharmacology

Develops drugs targeting eicosanoids, endocannabinoids, and lipoxins to resolve neuroinflammation and neuropathic pain.

Presynaptic Plasticity and Release Probability

Examines pharmacological modulation of presynaptic calcium dynamics and short-term plasticity to enhance synaptic efficiency.

Autophagy-Lysosomal Pathway Enhancement

Develops mTOR inhibitors and autophagy activators to promote clearance of pathogenic protein aggregates in neurodegeneration.

Dendritic Spine Morphogenesis Pharmacology

Investigates drugs targeting cofilin, actin dynamics, and spine stabilization proteins to enhance learning and memory.

Sleep-Wake Homeostasis Modulation

Studies pharmacological manipulation of adenosine accumulation, sleep pressure, and circadian oscillators in insomnia therapy.

Neuronal Calcium Buffering Capacity Enhancement

Develops drugs that augment parvalbumin and calretinin expression to protect neurons from excitotoxic calcium overload.

Reactive Oxygen Species Detoxification

Investigates pharmacological enhancement of superoxide dismutase, catalase, and glutathione peroxidase in oxidative stress-related neuropathology.

Oligodendrocyte Differentiation and Myelination

Studies drugs promoting oligodendrocyte maturation and myelin repair in demyelinating diseases and white matter disorders.

Neuronal Intrinsic Excitability Modulation

Examines pharmacological targeting of potassium channels, A-type currents, and adaptation mechanisms to regulate neuronal firing properties.

Chronic Pain Centralization Prevention Pharmacology

Develops drugs that prevent transition from acute to chronic pain through modulation of spinal sensitization and central amplification.

Cognitive Reserve Enhancement Pharmacology

Investigates drugs that promote brain plasticity and compensatory mechanisms to delay cognitive decline in aging and neurodegeneration.

Synaptic Tagging and Capture Mechanisms

Studies pharmacological enhancement of immediate-early gene products and plasticity-related proteins to strengthen specific synapses during learning.

Perineuronal Net Degradation and Plasticity

Develops drugs targeting matrix metalloproteinases and chondroitinase to degrade perineuronal nets and enhance neural plasticity.

Neuronal Migration and Axonal Guidance

Investigates pharmacological modulation of semaphorins, netrins, and adhesion molecules to guide neural development and regeneration.

Dopamine Stabilizers and Psychosis Treatment

Develops partial dopamine D2 agonists and stabilizers with improved efficacy and reduced extrapyramidal side effects.

Stress Hormone Receptor Antagonism Resilience

Studies glucocorticoid and mineralocorticoid receptor modulation to enhance stress resilience and prevent PTSD development.

Vestibular System Pharmacological Modulation

Examines drugs targeting vestibular neurotransmission for vertigo, motion sickness, and balance disorder management.

Neural Progenitor Cell Proliferation Control

Develops drugs that modulate neural stem cell differentiation and proliferation for regenerative therapy in neurological disorders.

Norepinephrine Transporter Inhibitor Specificity

Investigates selective NET inhibitors with minimal serotonin and dopamine transporter interactions for ADHD and depression.

Spinal Cord Injury Neuroprotection Strategy

Studies combination pharmacotherapy targeting inflammation, excitotoxicity, and apoptosis after traumatic spinal cord injury.

Vestibular Nucleus Pharmacological Mapping

Investigates selective neurotransmitter receptor modulation in vestibular nuclei to treat motion sensitivity and balance disorders.

Hippocampal-Cortical Dialogue Enhancement

Develops drugs that enhance communication between hippocampus and cortex to improve memory consolidation and recall.

Neuronal Metabolic Flexibility Promotion

Studies pharmacological enhancement of mitochondrial metabolism switching and ketone body utilization in neurodegenerative disease.

Immune-Privileged Site Barrier Function

Investigates drugs that preserve or enhance blood-brain barrier and blood-spinal cord barrier integrity during neuroinflammation.

Reward Prediction Error Signaling Modulation

Studies pharmacological targeting of dopamine phasic responses and reward encoding for addiction and motivation disorders.

Interhemispheric Coordination Pharmacology

Examines drugs modulating corpus callosum transmission and callosal integration for cognitive and motor coordination disorders.

Sensory Gating and Attentional Filtering

Investigates pharmacological enhancement of sensory gating mechanisms and prepulse inhibition in schizophrenia and ADHD.

Pericyte-Endothelial Cell Coupling Modulation

Studies drugs targeting pericyte function and vascular stability to improve cerebral blood flow and neuroprotection.

Mesolimbic Reward Circuit Dysregulation

Develops selective modulators of ventral tegmental area and nucleus accumbens function for anhedonia and motivational deficits.

Anesthetic Neuroprotection Mechanisms Exploration

Investigates neuroprotective properties of anesthetics beyond sedation in perioperative and acute neurological injury settings.

Infraslow Oscillation Pharmacological Modulation

Studies drugs targeting ultra-slow cortical rhythms and brain state transitions for consciousness and anesthesia research.

Sensorimotor Gating and Motor Inhibition

Examines pharmacological enhancement of motor response inhibition and impulse control in movement and neuropsychiatric disorders.

Thalamocortical Relay Pharmacology

Investigates drugs modulating thalamic gating and thalamocortical oscillations for sensory processing and consciousness disorders.

Central Pattern Generator Modulation

Studies pharmacological targeting of brainstem and spinal cord rhythm-generating networks for gait and breathing disorders.

Neuropathic Pain Facilitated Plasticity Prevention

Develops drugs preventing long-term potentiation-like changes in pain pathways that sustain chronic neuropathic pain states.

Retinogeniculate Synapse Plasticity Modulation

Investigates pharmacological enhancement of visual plasticity and critical period reopening in amblyopia and vision loss.

Anterior Insula Interoception Enhancement

Studies drugs modulating insular cortex function to improve interoceptive awareness and emotional regulation in psychiatric disorders.

Presynaptic GABA-B Receptor Autoregulation

Investigates feedback inhibition mechanisms through GABA-B autoreceptors and their pharmacological modulation for seizure control.

Cannabinoid CB2 Receptor Immunomodulation

Explores peripheral and central CB2 signaling as a non-psychoactive approach to neuroinflammatory disease treatment.

Acetylcholinesterase Inhibitor Drug Resistance

Examines mechanisms of compensatory upregulation and resistance development following prolonged acetylcholinesterase inhibition therapy.

Bradykinin B1 Receptor Antagonism Neuropathic Pain

Targets bradykinin B1 receptor upregulation in chronic pain states as a selective analgesic approach.

Neuronal Nitric Oxide Synthase Selective Inhibition

Develops isoform-selective nNOS inhibitors to prevent excitotoxic nitric oxide overproduction without affecting vascular function.

Vesicular Monoamine Transporter Modulation

Investigates VMAT2 inhibition and activation for neuropsychiatric disorders and neuroprotection strategies.

Lymphatic-Glymphatic System Pharmacology

Explores pharmacological enhancement of glymphatic clearance to remove neurotoxic protein aggregates and metabolic waste.

Formyl Peptide Receptor Neuroinflammation

Characterizes FPR signaling in microglial migration and activation for targeted anti-inflammatory intervention.

Mitochondrial Complex I Dysfunction Pharmacotherapy

Develops drugs targeting impaired oxidative phosphorylation in neurodegenerative diseases through bioenergetic restoration.

Gap Junction Connexin-43 Modulation

Investigates connexin-43 inhibition and enhancement for controlling pathological astrocytic coupling in epilepsy and stroke.

Hyperpolarization-Activated Cyclic Nucleotide Channel

Develops selective HCN channel modulators for heart rate-independent cognitive and neurological disease treatment.

Liquid-Liquid Phase Separation Neurodegeneration

Targets abnormal biomolecular condensates in ALS and FTD through pharmacological phase separation disruption.

Aquaporin-4 Water Channel Pharmacology

Develops AQP4 antagonists and agonists for controlling cerebral edema and glymphatic dysfunction.

Sodium-Hydrogen Exchanger Isoform Selectivity

Creates selective inhibitors of neuronal NHE isoforms to prevent calcium overload and excitotoxicity.

Nrf2 Antioxidant Response Activation

Develops Nrf2 activators that upregulate cytoprotective genes and antioxidant enzyme expression in neurodegeneration.

Metabotropic Glutamate mGluR8 Presynaptic Inhibition

Exploits mGluR8 agonism on glutamatergic terminals to reduce excessive excitatory neurotransmission in epilepsy.

Complement C5a Receptor Antagonism Neuroinflammation

Targets C5a receptor signaling to block complement cascade-mediated neuronal damage and microglial activation.

Sirtuin-1 Activators Longevity Pathways

Investigates SIRT1 activation for neuroprotection through NAD-dependent deacetylation of neurodegenerative substrates.

Cyclopamine and Smoothened Inhibition Development

Develops hedgehog signaling inhibitors for medulloblastoma and glioblastoma treatment with improved brain penetration.

Pannexin-1 Hemichannel Pharmacology

Investigates pannexin-1 inhibition to prevent ATP release and reduce neuroinflammatory cascade propagation.

Maternal Immune Activation Pharmacological Intervention

Develops interventions targeting maternal immune activation pathways to prevent neurodevelopmental psychiatric disorders.

Fatty Acid Amide Hydrolase Inhibition Selectivity

Creates FAAH inhibitors selective over FAAH-like enzyme to enhance endocannabinoid tone without off-target effects.

Iron Chelation Therapy Neurodegeneration

Develops brain-penetrant iron chelators to prevent redox cycling and oxidative stress in Parkinson''s disease.

Histone Acetyltransferase Inhibitors Memory

Explores HAT inhibition for reducing excessive chromatin remodeling and improving memory consolidation.

Caspase-3 Inhibition Apoptosis Prevention

Develops selective caspase-3 inhibitors to prevent neuronal apoptosis in acute and chronic neurodegenerative conditions.

Estrogen Receptor Beta Selective Agonists

Creates ER-beta selective ligands for neuroprotection and cognitive enhancement without reproductive side effects.

Dopamine Receptor Oligomerization Pharmacology

Investigates D2-D3 and D1-D5 receptor heteromerization and selective pharmacological targeting of complexes.

Neuregulin ErbB4 Signaling Schizophrenia

Targets neuregulin-1 and ErbB4 signaling dysregulation as a novel approach to schizophrenia treatment.

Dynorphin Kappa Opioid Receptor Depression

Develops kappa opioid antagonists to block dynorphin-mediated dysphoria and stress-related depressive symptoms.

Lactate Transporter Monocarboxylate Metabolism

Investigates MCT inhibitors and activators to optimize astrocyte-neuron metabolic coupling in energy crisis.

Reelin Signaling Restoration Schizophrenia

Develops pharmacological approaches to restore reelin expression and VLDLR signaling in cortical development.

Atypical Kinase Aurora B Inhibition

Targets Aurora B kinase dysfunction implicated in neurodegeneration and neurodevelopmental disease progression.

Prostaglandin EP4 Receptor Neuroprotection

Develops EP4 agonists to promote microglia-mediated neuroprotection and tissue repair after neural injury.

Insulin Receptor Signaling Brain Glucose

Investigates insulin receptor modulation for restoring glucose homeostasis and cognitive function in diabetes.

Toll-Like Receptor 7 and 9 Antagonism

Develops TLR7/9 antagonists to suppress autoimmune neuroinflammation in MS and CNS autoimmune disease.

Transglutaminase-2 Cross-Linking Inhibition

Targets pathological protein cross-linking by TG2 in tauopathies and prion-related diseases.

Neprilysin Augmentation Amyloid Clearance

Develops neprilysin activators and substrate modulators to enhance endogenous amyloid-beta degradation pathways.

Neuronal Ceroid Lipofuscinosis Lysosomal Therapy

Develops pharmacological approaches to enhance lysosomal degradation and clearance in neuronal storage diseases.

Synaptotagmin Calcium Sensor Modulation

Investigates selective modulation of synaptotagmin isoforms to enhance or inhibit neurotransmitter release.

RNA-Dependent Protein Kinase eIF2 Pathway

Develops PKR inhibitors to prevent eIF2-alpha phosphorylation-induced protein synthesis shutdown in neurodegeneration.

Endosomal-Lysosomal Acidification Pharmacology

Investigates V-ATPase modulators for controlling lysosomal pH-dependent proteolysis and amyloid processing.

Retrograde Axonal Transport BDNF Signaling

Develops enhancers of retrograde BDNF transport and TrkB signaling for neurodegenerative disease neuroprotection.

Protein Disulfide Isomerase Unfolded Protein Response

Targets PDI-mediated protein folding and ER stress response for misfolded protein diseases.

Axon Initial Segment Plasticity Pharmacology

Investigates AIS protein modulation to restore intrinsic excitability and compensate for dendritic dysfunction.

Dendritic Spine Maturation AMPA Receptor Trafficking

Develops pharmacological enhancers of GluA1-containing AMPA receptor insertion for cognitive enhancement.

Extracellular Matrix Remodeling MMP Regulation

Targets matrix metalloproteinase activity to control perineuronal net degradation and synaptic plasticity.

Mitochondrial Permeability Transition Pore Closure

Develops cyclophilin D inhibitors and other mPTP modulators to prevent mitochondrial-driven apoptosis.

Branched-Chain Amino Acid Metabolism Neurodegeneration

Investigates BCAA metabolism modulation for treating maple syrup urine disease and related aminoacidopathies.

Cyclin-Dependent Kinase Inhibition Tau Phosphorylation

Develops CDK5 and GSK3-beta selective inhibitors to reduce pathological tau hyperphosphorylation.

Heme Oxygenase-1 Induction Carbon Monoxide

Exploits HO-1 upregulation and endogenous CO production for neuroprotection in ischemic injury.